On September 8, 2022 GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary natural killer (NK) cell engager, TriKE platform, reported that management will present in-person at H.C. Wainwright’s 24th Annual Global Investment Conference taking place September 12-14, 2022 at the Lotte New York Palace (Press release, GT Biopharma, SEP 8, 2022, https://ir.gtbiopharma.com/news/detail/257/gt-biopharma-to-participate-in-the-h-c-wainwright-24th-annual-global-investment-conference-in-september [SID1234619249]). Company management will also be participating in 1×1 meetings during the event.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright 24th Annual Global Investment Conference – September 12-14, 2022

Title: GT Biopharma (GTBP) Company Presentation
Date: Tuesday, September 13, 2022
Time: 10:30 – 11:00 am EDT
Location: Kennedy II, 4th Floor, Lotte New York Palace
Webcast Link: Register here
*a replay of the presentation will be available for 90 days
If you are interested in arranging a 1×1 meeting request with management, please contact your bank conference representative. To access the archived recording for replay, please see the Presentations section of GT Biopharma’s corporate website.